Related Experiment Videos
Early cutaneous lesions secondary to hydroxyurea therapy
F Radaelli1, R Calori, P Faccini
1Serivzio di Ematologia, Istituto di Scienze Mediche, Università di Milano, Ospedale Maggiore, I.R.C.C.S., Milan, Italy.
American Journal of Hematology
|May 20, 1998
Summary
Hydroxyurea can cause skin lesions, but a patient with essential thrombocythemia developed hand ulcers rapidly after starting this cytostatic agent. This case highlights a rare, fast-onset adverse reaction to hydroxyurea therapy.
Area of Science:
- Oncology
- Dermatology
- Hematology
Background:
- Hydroxyurea is a standard cytostatic agent for myeloproliferative neoplasms like essential thrombocythemia.
- Cutaneous adverse reactions to hydroxyurea are known but typically manifest after prolonged therapy (years).
- Reported incidence of hydroxyurea-induced skin lesions ranges from 10% to 35%, with a 2% incidence in the authors' center.
Observation:
- A patient diagnosed with essential thrombocythemia was initiated on hydroxyurea treatment.
- The patient presented with the development of ulcers specifically on the hands.
- These ulcers appeared unusually rapidly, within 15 days of commencing hydroxyurea therapy.
Findings:
- The case describes an atypical and rapid onset of cutaneous lesions (hand ulcers) during hydroxyurea treatment.
- This presentation contrasts with the commonly reported delayed onset of such side effects.
- The patient's essential thrombocythemia diagnosis and hydroxyurea treatment are key factors.
Implications:
- This case suggests that hydroxyurea can induce cutaneous ulcers much earlier than typically observed.
- Clinicians should be vigilant for rapid-onset skin toxicity even in the early stages of hydroxyurea therapy.
- Further investigation into risk factors for early hydroxyurea-induced dermatologic adverse events may be warranted.